{"title":"细胞外囊泡衍生的lncRNA-GC1可作为预测和监测胃癌患者免疫治疗结果的新型生物标志物。","authors":"Jiangpeng Wei, Xinxin Wang, Danhong Dong, Yi Ru, Lubin Chen, Xin Cheng, Xiaohui Lv, Xin Guo","doi":"10.1186/s12916-025-04270-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Efforts to predict the outcomes of patients with gastric cancer (GC) following immune checkpoint inhibitor (ICI) treatments remain limited, owing to a lack of reliable biomarkers. Studies have found that extracellular vesicle (EV)-derived lncRNA-GC1 may serve as a GC-specific biomarker. This study was designed to expand on these previous results by estimating the usefulness of EV-derived lncRNA-GC1 as a predictive indicator for patients with GC who undergo ICI treatments.</p><p><strong>Methods: </strong>EV-derived lncRNA-GC1 levels were measured using real-time polymerase chain reaction (RT-PCR) in patients with unresectable or metastatic GC who were receiving ICI treatments. Correlations between this biomarker and ICI treatment outcomes were analyzed in a training cohort (n = 136), two external validation cohorts (n = 188 and n = 214), one expanding cohort (n = 30), and one prospective cohort (n = 192).</p><p><strong>Results: </strong>Circulating EVs exhibited a lncRNA-GC1 expression profile that was distinct from that of tissues or circulating cells. EV-derived lncRNA-GC1 levels were found to be independent of PD-L1 expression status or the density of CD8<sup>+</sup> T cell infiltration. EV-derived lncRNA-GC1 could be used to effectively predict ICI-related patient outcomes, and could be used for dynamic monitoring throughout treatments. Lower levels of EV-derived lncRNA-GC1 were associated with tumor microenvironmental characteristics such as more robust antitumor immunity-including higher levels of activated CD8<sup>+</sup> T/NK cells and an increased TH1/TH2 ratio. Such biomarkers can be stably detected in clinical practice. These results were consistent in both the two external validation cohorts and the one prospective cohort.</p><p><strong>Conclusions: </strong>EV-derived lncRNA-GC1 can be used to reliably predict immunotherapeutic outcomes in patients with GC who undergo ICI treatments, suggesting that targeted analyses of this lncRNA may be useful for guiding treatment planning, monitoring, and associated decision-making processes.</p>","PeriodicalId":9188,"journal":{"name":"BMC Medicine","volume":"23 1","pages":"499"},"PeriodicalIF":8.3000,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12392478/pdf/","citationCount":"0","resultStr":"{\"title\":\"Extracellular vesicle-derived lncRNA-GC1 serves as a novel biomarker for predicting and monitoring the immunotherapeutic outcomes of patients with gastric cancer.\",\"authors\":\"Jiangpeng Wei, Xinxin Wang, Danhong Dong, Yi Ru, Lubin Chen, Xin Cheng, Xiaohui Lv, Xin Guo\",\"doi\":\"10.1186/s12916-025-04270-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Efforts to predict the outcomes of patients with gastric cancer (GC) following immune checkpoint inhibitor (ICI) treatments remain limited, owing to a lack of reliable biomarkers. Studies have found that extracellular vesicle (EV)-derived lncRNA-GC1 may serve as a GC-specific biomarker. This study was designed to expand on these previous results by estimating the usefulness of EV-derived lncRNA-GC1 as a predictive indicator for patients with GC who undergo ICI treatments.</p><p><strong>Methods: </strong>EV-derived lncRNA-GC1 levels were measured using real-time polymerase chain reaction (RT-PCR) in patients with unresectable or metastatic GC who were receiving ICI treatments. Correlations between this biomarker and ICI treatment outcomes were analyzed in a training cohort (n = 136), two external validation cohorts (n = 188 and n = 214), one expanding cohort (n = 30), and one prospective cohort (n = 192).</p><p><strong>Results: </strong>Circulating EVs exhibited a lncRNA-GC1 expression profile that was distinct from that of tissues or circulating cells. EV-derived lncRNA-GC1 levels were found to be independent of PD-L1 expression status or the density of CD8<sup>+</sup> T cell infiltration. EV-derived lncRNA-GC1 could be used to effectively predict ICI-related patient outcomes, and could be used for dynamic monitoring throughout treatments. Lower levels of EV-derived lncRNA-GC1 were associated with tumor microenvironmental characteristics such as more robust antitumor immunity-including higher levels of activated CD8<sup>+</sup> T/NK cells and an increased TH1/TH2 ratio. Such biomarkers can be stably detected in clinical practice. These results were consistent in both the two external validation cohorts and the one prospective cohort.</p><p><strong>Conclusions: </strong>EV-derived lncRNA-GC1 can be used to reliably predict immunotherapeutic outcomes in patients with GC who undergo ICI treatments, suggesting that targeted analyses of this lncRNA may be useful for guiding treatment planning, monitoring, and associated decision-making processes.</p>\",\"PeriodicalId\":9188,\"journal\":{\"name\":\"BMC Medicine\",\"volume\":\"23 1\",\"pages\":\"499\"},\"PeriodicalIF\":8.3000,\"publicationDate\":\"2025-08-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12392478/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12916-025-04270-0\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12916-025-04270-0","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Extracellular vesicle-derived lncRNA-GC1 serves as a novel biomarker for predicting and monitoring the immunotherapeutic outcomes of patients with gastric cancer.
Background: Efforts to predict the outcomes of patients with gastric cancer (GC) following immune checkpoint inhibitor (ICI) treatments remain limited, owing to a lack of reliable biomarkers. Studies have found that extracellular vesicle (EV)-derived lncRNA-GC1 may serve as a GC-specific biomarker. This study was designed to expand on these previous results by estimating the usefulness of EV-derived lncRNA-GC1 as a predictive indicator for patients with GC who undergo ICI treatments.
Methods: EV-derived lncRNA-GC1 levels were measured using real-time polymerase chain reaction (RT-PCR) in patients with unresectable or metastatic GC who were receiving ICI treatments. Correlations between this biomarker and ICI treatment outcomes were analyzed in a training cohort (n = 136), two external validation cohorts (n = 188 and n = 214), one expanding cohort (n = 30), and one prospective cohort (n = 192).
Results: Circulating EVs exhibited a lncRNA-GC1 expression profile that was distinct from that of tissues or circulating cells. EV-derived lncRNA-GC1 levels were found to be independent of PD-L1 expression status or the density of CD8+ T cell infiltration. EV-derived lncRNA-GC1 could be used to effectively predict ICI-related patient outcomes, and could be used for dynamic monitoring throughout treatments. Lower levels of EV-derived lncRNA-GC1 were associated with tumor microenvironmental characteristics such as more robust antitumor immunity-including higher levels of activated CD8+ T/NK cells and an increased TH1/TH2 ratio. Such biomarkers can be stably detected in clinical practice. These results were consistent in both the two external validation cohorts and the one prospective cohort.
Conclusions: EV-derived lncRNA-GC1 can be used to reliably predict immunotherapeutic outcomes in patients with GC who undergo ICI treatments, suggesting that targeted analyses of this lncRNA may be useful for guiding treatment planning, monitoring, and associated decision-making processes.
期刊介绍：
BMC Medicine is an open access, transparent peer-reviewed general medical journal. It is the flagship journal of the BMC series and publishes outstanding and influential research in various areas including clinical practice, translational medicine, medical and health advances, public health, global health, policy, and general topics of interest to the biomedical and sociomedical professional communities. In addition to research articles, the journal also publishes stimulating debates, reviews, unique forum articles, and concise tutorials. All articles published in BMC Medicine are included in various databases such as Biological Abstracts, BIOSIS, CAS, Citebase, Current contents, DOAJ, Embase, MEDLINE, PubMed, Science Citation Index Expanded, OAIster, SCImago, Scopus, SOCOLAR, and Zetoc.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
